Finerenone

• CAT Number: I006795
• CAS Number: 1050477-31-0
• Molecular Formula: C21H22N4O3
• Molecular Weight: 378.432
• Purity: ≥95%
• Solubility: Soluble in DMSO, not in water
• Storage: 0 - 4°C for short term or -20 °C for long term
• IUPAC Name: (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide
• InChI: InChI=1S/C21H22N4O3/c1-5-28-21-18-17(14-7-6-13(9-22)8-15(14)27-4)16(20(23)26)12(3)25-19(18)11(2)10-24-21/h6-8,10,17,25H,5H2,1-4H3,(H2,23,26)/t17-/m1/s1
• InChIKey: BTBHLEZXCOBLCY-QGZVFWFLSA-N
• SMILES: CCOC1=NC=C(C2=C1C(C(=C(N2)C)C(=O)N)C3=C(C=C(C=C3)C#N)OC)C

Finerenone(CAT: I006795), also known as BAY94-8862, is a non-steroidal antimineralocorticoid that is in phase III clinical trials for the treatment of chronic heart failure. It has a less relative affinity to other steroid hormone receptors than currently available antimineralocorticoids such as eplerenone and spironolactone, which should result in fewer adverse effects like gynecomastia. This product is used for medical research and development and other scientific research purposes.

Reference

1:Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Protects Against Acute Kidney Injury-Mediated Chronic Kidney Disease: Role of Oxidative Stress. Lattenist L, Lechner SM, Messaoudi S, Le Mercier A, El Moghrabi S, Prince S, Bobadilla NA, Kolkhof P, Jaisser F, Barrera-Chimal J.Hypertension. 2017 May;69(5):870-878. doi: 10.1161/HYPERTENSIONAHA.116.08526. Epub 2017 Mar 20. PMID: 28320854
2:Finerenone in diabetic kidney disease – So far, so good. Gilbert RE.J Diabetes Complications. 2017 Apr;31(4):651-652. doi: 10.1016/j.jdiacomp.2016.12.012. Epub 2017 Jan 20. No abstract available. PMID: 28153675
3:A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy. Katayama S, Yamada D, Nakayama M, Yamada T, Myoishi M, Kato M, Nowack C, Kolkhof P, Yamasaki Y; ARTS-DN Japan study group..J Diabetes Complications. 2017 Apr;31(4):758-765. doi: 10.1016/j.jdiacomp.2016.11.021. Epub 2016 Dec 14. PMID: 28025025 Free Article
4:Masked and Nocturnal Hypertension in the ARTS-DN ABPM Sub-Study with Finerenone. Ruilope LM, Nowack C, Bakris GL.J Am Soc Hypertens. 2016 Jul;10 Suppl 1:e7. doi: 10.1016/j.jash.2016.06.021. No abstract available. PMID: 27677144
5:The novel mineralocorticoid receptor antagonist finerenone in diabetic kidney disease: Progress and challenges. Yang P, Huang T, Xu G.Metabolism. 2016 Sep;65(9):1342-9. doi: 10.1016/j.metabol.2016.06.001. Epub 2016 Jun 12. Review. No abstract available. PMID: 27506741
6:Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone (BAY 94-8862) in Individuals With Renal Impairment. Heinig R, Kimmeskamp-Kirschbaum N, Halabi A, Lentini S.Clin Pharmacol Drug Dev. 2016 Nov;5(6):488-501. doi: 10.1002/cpdd.263. Epub 2016 Jul 18. PMID: 27431783
7:Heart failure: Finerenone vs eplerenone for patients with HFrEF. Huynh K.Nat Rev Cardiol. 2016 Jul;13(7):381. doi: 10.1038/nrcardio.2016.82. Epub 2016 May 19. No abstract available. PMID: 27194086
8:Finerenone in heart failure: walking a fine line. Naegele M, Hernandez AF, Ruschitzka F.Eur Heart J. 2016 Jul 14;37(27):2115-7. doi: 10.1093/eurheartj/ehw155. Epub 2016 Apr 29. No abstract available. PMID: 27130706
9:A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Filippatos G, Anker SD, Böhm M, Gheorghiade M, Køber L, Krum H, Maggioni AP, Ponikowski P, Voors AA, Zannad F, Kim SY, Nowack C, Palombo G, Kolkhof P, Kimmeskamp-Kirschbaum N, Pieper A, Pitt B.Eur Heart J. 2016 Jul 14;37(27):2105-14. doi: 10.1093/eurheartj/ehw132. Epub 2016 Apr 29. PMID: 27130705 Free PMC Article
10:Finerenone: a New Mineralocorticoid Receptor Antagonist Without Hyperkalemia: an Opportunity in Patients with CKD? Haller H, Bertram A, Stahl K, Menne J.Curr Hypertens Rep. 2016 Apr;18(5):41. doi: 10.1007/s11906-016-0649-2. Review. PMID: 27115525